UnitedHealth Group Incorporated · UNH · FY2025 Q3 · Calendar Q4 2025

UnitedHealth outlines repricing and operational reset for 2026

The supplied analysis supports a cautiously constructive operating thesis: repricing, network optimization, Optum Rx demand and Optum Insight AI investments could support recovery, but membership pressure, medical costs, funding cuts and execution risks remain material.

Why did UNH rise 0.5% after beating EPS estimates in FY2025 Q3?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNYSEHealthcare $337.74B market cap
90quality score

Earnings scorecard

Reported versus consensus
Reported EPS $2.92 Consensus $2.80
EPS surprise +4.3% Reported versus consensus
Reported revenue $113.16B Consensus $113.03B
Revenue surprise +0.1% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move +0.5% Event window
SPY move +0.3% Same window
Abnormal move +0.2% Stock minus SPY
Volume 2.4× Versus trailing sessions
Subsequent drift -11.3% Up to 20 sessions
UNHSPY benchmark

Ask FN2 about UNH FY2025 Q3

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Management highlighted new Optum Insight AI products, completed the Amedisys acquisition, and outlined a targeted reduction in Optum Health membership to refocus on higher-performing value-based contracts.

Guidance delta

Formal 2026 guidance was not provided; management plans to release it with Q4 results in January.

Key takeaways

  • Management expects repricing across Medicare Advantage, commercial and ACA products to support 2026 margin recovery.
  • Optum Health is narrowing its provider network and exiting low-performing PPO contracts to refocus on value-based care.
  • Capital deployment is paused during debt reduction and Amedisys integration; buybacks are planned to resume in the second half of 2026.
  • Optum Insight AI products and Optum Rx growth remain part of the longer-term expansion plan.

Management priorities

  • Execute pricing and network changes across UnitedHealthcare and Optum Health.
  • Integrate Amedisys while reducing leverage before resuming capital deployment.
  • Expand Optum Insight AI and payment-integrity initiatives.
  • Scale Optum Rx rebate pass-through and continue value-based care contracting.

Follow UNH with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
UNH EPS earnings history estimate and actual scatter chart 10 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $5.98 Q4 '23 actual $6.16, beat Q1 '24 estimate $6.61 Q1 '24 actual $6.91, beat Q2 '24 estimate $6.65 Q2 '24 actual $6.80, beat Q3 '24 estimate $7.01 Q3 '24 actual $7.15, beat Q2 '25 estimate $4.45 Q2 '25 actual $4.08, miss Q3 '25 estimate $2.80 Q3 '25 actual $2.92, beat Q4 '25 estimate $2.10 Q4 '25 actual $2.11, match Q1 '26 estimate $6.46 Q1 '26 actual $7.23, beat Q2 '26 estimate $4.94 Q2 '26 actual $6.38, beat Q3 '26 estimate $4.14 Q3 '26 actual $4.69, beat Q4 '26 estimate $2.28 Q1 '27 estimate $8.14 Q2 '27 estimate $6.92 Q3 '27 estimate $5.36
Show less

Analyst Consensus ?

ConsensusBuy52 ratings
Bullish4382.7%
Neutral713.5%
Bearish23.8%

Analyst 52W Price Targets

$339.85Current
$327Low
$492.92Average
$650High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Wells Fargo Overweight OverweightMaintainOct 27, 2026
Morgan Stanley Overweight OverweightMaintainOct 27, 2026
Mizuho Outperform OutperformMaintainOct 22, 2026
RBC Capital Outperform OutperformMaintainOct 20, 2026
JP Morgan Overweight OverweightMaintainOct 16, 2026
Show 47 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $339.85. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
TD CowenRyan Langston$455$330.48 +33.9%Nov 20, 2026
Morgan StanleyAnalyst unavailable$531$410.7 +56.2%Oct 27, 2026
Wells FargoStephen Baxter$487$410.7 +43.3%Oct 27, 2026
Mizuho SecuritiesAnalyst unavailable$500$417 +47.1%Oct 22, 2026
RBC CapitalBen Hendrix$498$406.88 +46.5%Oct 20, 2026
See 137 more

Track every rating change on UNH the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

UnitedHealth Group Incorporated (UNH) operates as a comprehensive healthcare enterprise across the United States, structuring its diverse services into four key divisions: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment provides a wide array of health benefit plans and consumer-focused services. These offerings cater to a broad spectrum of clients, including large national corporations, public sector employers, mid-sized and small businesses, and individual consumers. It also delivers specialized health coverage and wellness programs tailored for individuals aged 50 and older, addressing their needs for preventive and acute care, chronic disease management, and other age-specific health issues. This division further encompasses Medicaid plans, children's health insurance, dental benefits, and various hospital and clinical services. Optum Health focuses on delivering direct healthcare solutions and management services.…

Historical context

All UNH earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the UNH recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-10-05T00:20:41.745039+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-05T00:20:41.742407+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-05. For educational purposes only; not investment advice.